Event Abstract

Fucoidan: a marine polysaccharide for SPECT diagnosis of thrombosis

  • 1 INSERM, University Paris 13, University Paris Diderot, Sorbonne Paris Cité University, Laboratory for Vascular Translational Science, INSERM U1148, France
  • 2 Algues et Mer, France
  • 3 Paris Diderot University, Multimodal Imaging Research Federation, France
  • 4 Bichat-Claude Bernard Hospital, APHP, Nuclear Medicine Department, France

Cardiovascular pathologies represent one of the main causes of death and morbidity in the world[1]. Fucoidans, sulfated polysaccharides extracted from brown algae are versatile biomolecules endowed with numerous biological activities[2]-[7]. In particular, a low molecular weight fucoidan (LMWF), able to strongly bind to P-selectin, allowed the diagnosis of vascular thrombosis and ischemia by SPECT imaging with 99mTc in rat models[8]-[10].

The radiolabeling studies proceeded by straightly mixing a saline solution of LMWF with 99mTcO4- in appropriate conditions without any chemical modification of the polysaccharide[9]. As part of a joint laboratory with the French company Algues & Mer which produces the LMWF, our works aim to obtain a contrast agent kit for the clinical SPECT imaging of atherothrombosis and heart ischemia.

Materials and Methods: LMWF is prepared by an aqueous treatment of Ascophyscient®, a polysaccharidic extract from Ascophyllum nodosum (Algues & Mer, Ouessant, France)[10]. Molecular weights were determined using HPSEC-MALLS-dRI[9]. Colorimetric assays led to fucose[11], uronic acid[12] and sulfate[13] contents and the neutral sugar composition was obtained by acid hydrolysis of LMWF and HPAEC analysis with amperometric detection. The contrast agent was prepared by mixing a solution of ascorbic acid, tin chloride and sodium chloride and another one containing the LMWF and sodium chloride. 99mTcO4- was added just before injection.

Results and Discussion: Fucoidans are natural polymers and their chemical compositions vary depending on the species, water temperature and the harvest period of the algae. For the preparation of a clinical contrast agent, LMWF had to present well-defined and reproducible physicochemical features. Numerous batches of LMWF have been purified from Ascophyscient® and analyzed to provide these parameters.

The average molecular weights were about 8,000 Da. Fucose and sulfate, as part of the key features responsible for the biological activities of fucoidans[14],[15], and uronic acids constitute about 80% (w/w) of the polymer, with a few amounts of xylose, glucose, galactose and mannose as the remaining 20%.

A radiolabelling kit was prepared, all reactants being kept lyophilized until the radiolabelling with a saline solution of 99mTcO4-. Purity was >95%. The biodistribution study in rat of both compounds labeled with 99mTc evidenced a predominant renal elimination of the purified fucoidan, whereas the crude fucoidan (Ascophyscient®) was mainly retained in liver and spleen. SPECT imaging of rat models have shown the effectiveness and the selectivity of 99mTc-LMWF toward pathological myocardium (figure). All this work is part of a large-scale european project (NanoAthero).

Conclusion: This purified sulfated polysaccharide appears promising for the development of molecular imaging in acute coronary syndrome and a clinical trial will start on 2016.

ANR LabCom; ANR FucoThrombo; ANRT for CIFRE fellowship n°2014/0337 (Lucas Chollet); Large-scale integrated project NanoAthero (NMP-2012-309820)

References:
[1] Finegold, J.A.; Asaria, P.; Francis, D.P. Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int. J. Cardiol. 2013, 168, 934–945.
[2] Chaubet, F.; Chevolot, L.; Jozefonvicz, J.; Durand, P.; Boisson-Vidal, C. Retationships between chemical characteristics and anticoagulant activity of low molecular weight fucans from marine algae. B.S.P aulsen( ed.). Bioact. Carb. Polymers. 2000. 59-84.
[3] Maka, W.; Hamida, N.; Liua, T.; Lua, J.; Whitea, W.L. Fucoidan from New Zealand Undaria pinnatifida: Monthly variations and determination of antioxidant activities. Carbohydrate Polymers. 2013, 95, 606– 614.
[4] Abu, R.; Jiang, Z.; Ueno, M.; Isaka, S.; Nakazono, S.; Okimura, T.; Cho, K.;Yamaguchi, K.; Kim, D.; Oda, T. Anti-metastatic effects of the sulfated polysaccharide ascophyllan isolated from Ascophyllum nodosum on B16 melanoma. Biochem Biophys. Res. Comm.. 2015, 1-6.
[5] Mourão, P.A.S. Perspective on the Use of Sulfated Polysaccharides from Marine Organisms as a Source of New Antithrombotic Drugs. Mar. Drugs 2015, 13, 2770-2784.
[6] Atashrazm, F.; Lowenthal, R.; Woods, G.; Holloway, A.; Dickinson, J. Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential. Mar. Drugs. 2015, 13, 2327-2346.
[7] Han, Y.S.; Hee Lee, J.; Hun Lee, S. Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling. Biomol. Ther. 2015, 23(3), 225-232.
[8] Bachelet, L.; Bertholon, I.; Lavigne, D.; Vassy, R.; Jandrot-Perrus, M.; Chaubet, F.; Letourneur, D. Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets. Biochim Biophys Acta 1790. 2009, 141–146.
[9] Rouzet, F.; Bachelet-Violette, L.; Alsac, J.M.; Suzuki, M.; Meulemans, A.; Louedec, L.; Petiet, A.; Jandrot-Perrus, M.; Chaubet, F.; Michel, J.B.; Le Guludec, D.; Letourneur, D. Radiolabeled Fucoidan as a P-Selectin Targeting Agent forIn Vivo Imaging of Platelet-Rich Thrombus and Endothelial Activation. J Nucl Med. 2011, 52 (9), 1433-1440.
[10] Saboural, P.; Chaubet, F.; Rouzet, F.; Al-Shoukr, F.; Azzouna, R. B.; Bouchemal, N.; Picton, L.; Louedec, L.; Maire, M.; Rolland, L.; Potier, G.; Le Guludec, D.; Letourneur, D.; Chauvierre, C. Purification of a Low Molecular Weight Fucoidan for SPECT Molecular Imaging of Myocardial Infarction. Mar. Drugs. 2014, 12, 4851-4867.
[11] Dische, Z. New Color Reactions for Determination of Sugars in Polysaccharides. In Methods of Biochemical Analysis; Glick, D., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 1955, 2, 313–358.
[12] Bitter, T.; Muir, H.M. A modified uronic acid carbazole reaction. Anal. Biochem. 1962, 4, 330–334.
[13] Gustafsson, L. Determination of ultramicro amounts of sulphate as methylene blue—II The reduction. Talanta 1960, 4, 236–243.
[14] Pomin, V.H. Fucanomics and galactanomics: Current status in drug discovery, mechanisms of action and role of the well-defined structures. Biochim. Biophys. Acta Gen. Subj. 2012, 1820, 1971–1979.
[15] Berteau, O.; Mulloy, B. Sulfated fucans, fresh perspectives: Structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology. 2003, 13, 29R–40R.

Keywords: Molecular Imaging, contrast agent, clinical application, Imaging method

Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016.

Presentation Type: General Session Oral

Topic: Imaging with biomaterials

Citation: Chollet L, Saboural PP, Rouzet F, Maire M, Aerts JJ, Louedec L, Al-Shoukr F, Aid RR, Potier GG, Le Guludec DD, Chauvierre CC, Letourneur DD and Chaubet FF (2016). Fucoidan: a marine polysaccharide for SPECT diagnosis of thrombosis. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.01999

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 27 Mar 2016; Published Online: 30 Mar 2016.